Phosphonate emerging zinc binding group in matrix metalloproteinase inhibitors

March 15, 2016
Phosphonate emerging zinc binding group in matrix metalloproteinase inhibitors
This research contains a comprehensive review of known phosphonate-based MMP inhibitors. Credit: Dr. Paolo Tortorella, Bentham Science Publishers

Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases, responsible for the degradation of the extracellular matrix (ECM). Their involvement has been demonstrated in several diseases, among which chronic inflammation and cancer; therefore, they have been considered interesting therapeutic targets. The design of MMP inhibitors (MMPIs) has largely focused on development of various compounds containing a zinc binding group (ZBG) in their structure, with the hydroxamate being the most potent one.

Currently, there are no MMPI containing hydroxamate function as ZBG in the market, mainly due to their proven toxicity. An alternative function chelating the ion would ensure a better selectivity. This latter aspect is mandatory to obtain clinically exploitable compounds. In this review the phosphonate and bis-phosphonate groups as the ZBG are considered in the development of selective and potent MMPIs.

The authors have been working since a long time on MMP inhibitors containing alternative zinc-binding to hydroxamate, focusing in particular on phosphonic acids, thus contributing to this still interesting research field.

Phosphonate-based are classified on peptide phosphonate; sulphonamide and sulfonyl phosphonate, the most potent; carbamoyl phosphonate, and bisphosphonate that have been identified more recently with an interesting activity on bone resorption.

Moreover, the binding with the MMP active site is discussed in the research paper, 'Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors', published in Current Drug Targets.

Explore further: Bacteria's secret weapon against pesticides and antibiotics revealed

More information: Cristina Campestre et al. Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors, Current Drug Targets (2015). DOI: 10.2174/1389450116666150113121733

Related Stories

New findings offer hope for diabetic wound healing

November 23, 2015

University of Notre Dame researchers have discovered a compound that accelerates diabetic wound healing, which may open the door to new treatment strategies. Non-healing chronic wounds are a major complication of diabetes, ...

Scientists discover a trigger of Alzheimer's disease

March 11, 2016

A group of the Lomonosov Moscow State University scientists, together with their colleagues from the Institute of Molecular Biology, Russian Academy of Sciences and the King's College London, determined the mechanism of Alzheimer's ...

Recommended for you

Efficient catalyst developed for producing pronucleotides

April 28, 2017

(—A team of researchers with Merck & Co., Inc. has developed an efficient catalyst for producing pronucleotides, paving the way perhaps to a new class of drugs for combatting viruses and cancer. In their paper ...

Tick protein helps antibiotics combat MRSA super bug

April 27, 2017

A protein derived from ticks enhances the effectiveness of antibiotic treatment for methicillin-resistant Staphylococcus aureus, or MRSA, according to a Yale-led study. The strategy of using the protein in combination with ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.